Association of Low-Attenuation Plaque with Impaired Glucose Tolerance and Type 2 Diabetes Mellitus in Patients with Suspected Coronary Artery Disease

Overview

Journal Biomedicines

Date 2025 Jan 25

PMID 39857612

Authors

Thomas R Andersen

Katrine S Overgaard

Laurits Juhl Heinsen

Roda Abdulkadir Mohamed

Helle Precht

Jess Lambrechtsen

Soren Auscher

Kenneth Egstrup

Affiliations

Soon will be listed here.

Abstract

Aim: The aim of this study was to evaluate the differences in plaque composition and burden between normal glycemic status (NGS) and dysglycemia expressed as impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM).

Methods: Clinically indicated coronary computed tomography angiography was used to evaluate patients with suspected coronary artery disease (CAD). An oral glucose tolerance test was performed to assess glycemic status. Patients were stratified as NGS, IGT, and T2DM. Plaque volumes were quantified using validated software, with further compositional measurements of low-attenuation, non-calcified, and calcified plaque burden.

Results: Of 355 patients with suspected CAD, 220 had NGS, 92 were diagnosed with IGT, and 43 with known T2DM. Low-attenuation plaque volume was significantly higher in IGT (209 mm, < 0.02) and T2DM (243 mm, = 0.005) compared with NGS (166 mm). Total plaque burden was similar between all groups, but a significantly greater low-attenuation plaque burden was seen in IGT ( = 0.03) and T2DM ( = 0.02) compared with NGS. The multivariate linear regression model adjusted for clinical risk factors showed that patients with IGT had a greater low-attenuation plaque burden compared with those with NGS ( = 0.03). Interestingly, no significant differences in plaque burdens were observed between those with IGT and T2DM in both univariate and multivariate analyses.

Conclusions: Dysglycemia, including impaired glucose tolerance and type 2 diabetes mellitus, was associated with increased low-attenuation plaque burden compared with normal glycemic status. Patients with IGT demonstrated plaque burden similar to patients with known T2DM, underscoring the need for early metabolic intervention.

References

Gaur S, Ovrehus K, Dey D, Leipsic J, Botker H, Jensen J . Coronary plaque quantification and fractional flow reserve by coronary computed tomography angiography identify ischaemia-causing lesions. Eur Heart J. 2016; 37(15):1220-7. PMC: 4830909. DOI: 10.1093/eurheartj/ehv690. View

Huang Y, Cai X, Mai W, Li M, Hu Y . Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016; 355:i5953. PMC: 5121106. DOI: 10.1136/bmj.i5953. View

Takagi H, Leipsic J, Indraratna P, Gulsin G, Khasanova E, Tzimas G . Association of Tube Voltage With Plaque Composition on Coronary CT Angiography: Results From PARADIGM Registry. JACC Cardiovasc Imaging. 2021; 14(12):2429-2440. DOI: 10.1016/j.jcmg.2021.07.011. View

Ross R . Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. DOI: 10.1056/NEJM199901143400207. View

Agatston A, Janowitz W, HILDNER F, Zusmer N, VIAMONTE Jr M, Detrano R . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15(4):827-32. DOI: 10.1016/0735-1097(90)90282-t. View

Bianchi C, Miccoli R, Bonadonna R, Giorgino F, Frontoni S, Faloia E . Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance. Diabetes Care. 2012; 35(12):2607-12. PMC: 3507559. DOI: 10.2337/dc11-2504. View

Williams M, Kwiecinski J, Doris M, McElhinney P, DSouza M, Cadet S . Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Circulation. 2020; 141(18):1452-1462. PMC: 7195857. DOI: 10.1161/CIRCULATIONAHA.119.044720. View

Hulman A, Vistisen D, Glumer C, Bergman M, Witte D, Faerch K . Glucose patterns during an oral glucose tolerance test and associations with future diabetes, cardiovascular disease and all-cause mortality rate. Diabetologia. 2017; 61(1):101-107. DOI: 10.1007/s00125-017-4468-z. View

Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A . Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999; 22(6):920-4. DOI: 10.2337/diacare.22.6.920. View

10.

Agarwal S, Morgan T, Herrington D, Xu J, Cox A, Freedman B . Coronary calcium score and prediction of all-cause mortality in diabetes: the diabetes heart study. Diabetes Care. 2011; 34(5):1219-24. PMC: 3114476. DOI: 10.2337/dc11-0008. View

11.

Hoffmann U, Ferencik M, Udelson J, Picard M, Truong Q, Patel M . Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain: Insights From the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation. 2017; 135(24):2320-2332. PMC: 5946057. DOI: 10.1161/CIRCULATIONAHA.116.024360. View

12.

Yahyavi S, Snorgaard O, Knop F, Schou M, Lee C, Selmer C . Prediabetes Defined by First Measured HbA Predicts Higher Cardiovascular Risk Compared With HbA in the Diabetes Range: A Cohort Study of Nationwide Registries. Diabetes Care. 2021; 44(12):2767-2774. DOI: 10.2337/dc21-1062. View

13.

Ostgren C, Otten J, Festin K, Angeras O, Bergstrom G, Cederlund K . Prevalence of atherosclerosis in individuals with prediabetes and diabetes compared to normoglycaemic individuals-a Swedish population-based study. Cardiovasc Diabetol. 2023; 22(1):261. PMC: 10537533. DOI: 10.1186/s12933-023-01982-6. View

14.

Qiao Q, Pyorala K, Pyorala M, Nissinen A, Lindstrom J, Tilvis R . Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J. 2002; 23(16):1267-75. DOI: 10.1053/euhj.2001.3113. View

15.

Lee S, Chang H, Sung J, Park H, Heo R, Rizvi A . Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study. JACC Cardiovasc Imaging. 2018; 11(10):1475-1484. DOI: 10.1016/j.jcmg.2018.04.015. View

16.

Gerstein H, Santaguida P, Raina P, Morrison K, Balion C, Hunt D . Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007; 78(3):305-12. DOI: 10.1016/j.diabres.2007.05.004. View

17.

Cao Z, Li W, Wen C, Li S, Chen C, Jia Q . Risk of Death Associated With Reversion From Prediabetes to Normoglycemia and the Role of Modifiable Risk Factors. JAMA Netw Open. 2023; 6(3):e234989. PMC: 10051049. DOI: 10.1001/jamanetworkopen.2023.4989. View

18.

Cersosimo E, DeFronzo R . Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 2006; 22(6):423-36. DOI: 10.1002/dmrr.634. View

19.

Richter B, Hemmingsen B, Metzendorf M, Takwoingi Y . Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database Syst Rev. 2018; 10:CD012661. PMC: 6516891. DOI: 10.1002/14651858.CD012661.pub2. View

20.

Borg R, Vistisen D, Witte D, Borch-Johnsen K . Comparing risk profiles of individuals diagnosed with diabetes by OGTT and HbA1c The Danish Inter99 study. Diabet Med. 2010; 27(8):906-10. DOI: 10.1111/j.1464-5491.2010.03034.x. View